| INTRODUC TI ON
Immune checkpoints are regulators of immune system activation, preventing autoimmunity and protecting tissues from immunologic collateral damage. 1 The binding of programmed cell death-1 (PD-1) on T lymphocytes and its ligands PD-L1 and PD-L2 on antigenpresenting cells results in reduced proliferation and suppressed activity of T cells to establish self-tolerance, thereby playing an inhibitory role in the normal immune response. 2 In malignant cancer, they are often hijacked by transformed cells to avoid the antitumor response by the immune system. 3 The existence of PD-1 + or PD-L1 + cells in tumor tissues has been reported to correlate to the poor prognosis of patients. 
K E Y W O R D S
aPKC, c-Myc, cutaneous angiosarcoma, FoxO1, PD-L1 some cancers, such as melanoma, non-small-cell lung carcinoma, or renal cell carcinoma. 6 Although the treatment of cancer patients with immune checkpoint blockers is a highly promising therapeutic approach yielding remarkable antitumor responses with limited sideeffects, only a proportion of patients respond to this treatment. 7 Further understanding of the regulation of PD-L1 expression will be important to improve immune checkpoint treatment. Recent work has shown that proto-oncogene c-Myc regulates PD-L1 expression in human tumor cells. 8 Cutaneous angiosarcoma (CAS) originates from endothelial cells in the vasculature and is a relatively rare, accounting for approximately 2% of soft-tissue sarcoma, but quite malignant tumor. 9 It arises mainly from the scalp of the elderly and frequently results in distant metastasis, especially lung metastasis, at an early stage.
Standard treatments for angiosarcoma include surgical resection, chemotherapy, and radiation therapy. Despite the improvement of these treatments in the last few decades, the mean 5-year survival rate of patients is approximately 33.5%, 10 suggesting the importance of developing new therapeutic strategies. We have recently reported that the polarity protein atypical protein kinase C lambda/ iota (aPKCλ) controls physiologic and pathologic endothelial proliferation through phosphorylation of the transcription factor Forkhead box O1 (FoxO1). Phosphorylation of the FoxO1 DNA-binding domain results in inhibiting its DNA binding ability, modulating microRNA (miR)34-c expression to control c-Myc expression. 11 Moreover, the presence of FoxO1 phosphorylation by aPKCλ shows a strong association with angiosarcoma patient prognosis. 11 The miR-34 family has been reported to directly interact with the promoter region of PD-L1 and regulate the expression of PD-L1 in an inhibitory manner in several human cancer cells. 12 In line with these observations, we hypothesized that aPKCλ regulates PD-L1 expression through the aPKCλ/FoxO1 signaling axis. We examined PD-L1 expression in CAS patient samples by immunostaining and found that PD-L1 expression was correlated with poor prognosis in CAS patients. Expression of PD-L1 associated with the expression level of aPKCλ and phosphorylation of FoxO1 at Ser218. Moreover, suppression of aPKCλ resulted in reduced PD-L1 expression in cultured endothelial cells.
Our results suggest a molecular mechanism controlling PD-L1 expression in CAS and the potential of the blockage of this pathway as a new therapeutic approach for CAS.
| MATERIAL S AND ME THODS

| Patients
Twenty-nine patients who were diagnosed with CAS at the Dermatology department of Okayama University (Okayama, Japan)
and Hokkaido University Hospital (Hokkaido, Japan) were examined retrospectively. Clinical information including patient age, sex, tumor site, stage, treatment, and survival was extracted from the medical records of these 2 hospitals. All samples were obtained at the time of biopsy for diagnosis after the proper informed consent. These studies were carried out in accordance with the Declaration of Helsinki. All slides were assessed using confocal laser scanning microscopy (SP8; Leica, Wetzlar, Germany). All images were analyzed by ImageJ (NIH, Bethesda, MD, USA). In addition to the, at least, partial presence of EC markers, transformed cells at the lesion were identified with abnormal nuclear features, which were visualized by DAPI staining. As previously reported, over 5% of membranous expression of PD-L1 at the tumor site was defined as positive. 13 Staining intensity and localization were evaluated by 2 investigators independently. Samples stained with only secondary Abs were used as a negative controls.
| Histological analysis
| Cell culture
We used pooled HUVECs that were purchased from Pelobiotech 
| Gene knockdown
SMART-pool ON-TARGET plus PRKCI were transfected with Oligofectamine (Invitrogen) in HUVECs and ASMs to achieve PRKCI knockdown. Scrambled siRNA was used for control. Total RNA of the cells was extracted 48 hours after transfection, and protein was extracted 72 hours after transfection.
| Sodium aurothiomalate hydrate treatment
Cells were treated with 100 μmol/L sodium aurothiomalate hydrate (ATM, Sigma, St. Louis, MO, USA), then total RNA or protein was extracted 48 hours or 72 hours after transfection, respectively.
Cells without ATM treatment were used for control.
| Reverse transcription-quantitative PCR
For the analysis of mRNA relative expression levels, total RNA was ex- All assays were carried out using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and analyzed by the comparative Ct method using the expression of beta2MG as an endogenous control.
| Western blot analysis
Cells were lysed with 1× SDS sample buffer, sonicated with a Bioruptor (Diagenode, Denville, NJ, USA) for the reduction of viscosity, and the protein concentration was determined using a BCA protein assay kit (Pierce, Waltham, MA, USA). Then 2% β-mercaptoethanol was added and boiled at 95°C for 10 minutes. 
| Immunohistolabelling of culture cells
Cells seeded on gelatin-coated cover slips were fixed with 4% para- tion; Thermo Fisher Scientific) at room temperature for 2 hours All slides were assessed using confocal laser scanning microscopy (SP8; Leica). All images were analyzed using ImageJ (NIH).
| Statistical analysis
Continuous variables were reported as mean ± SEM and were compared using Student's t test. P values < .05 were considered statistically significant. Patient survival rates were shown by Kaplan-Meier Data shown as n (%) unless otherwise indicated.
curves and compared by the log-rank test. All statistical analyses were undertaken using JMP Pro 13.0 (SAS, Cary, NC, USA) and Prism 5 software (GraphPad Software, La Jolla, CA, USA).
| RE SULTS
| Expression of PD-L1 correlates with poor prognosis of CAS patients
We have previously shown that the presence of pSer218 FoxO1
and high expression of aPKCλ in transformed cells in CAS are strongly correlated with poor patient prognosis. 11 Among these previously analyzed samples, those from 29 patients at the time of biopsy for initial diagnosis were used for further analysis due to sample availability. Patient characteristics are summarized in Table 1 . The average age of the patients was 76.1 years, and 62.1% of the patients (n = 18) were men. The primary tumor sites were parietal in most patients (n = 25, 86.2%), and the clinical stage of the most patients was stage I (n = 21, 72.4%). Almost all patients were subsequently treated with chemotherapy and radiation therapy (Table 1 ).
All samples were analyzed by immunostaining using Abs against PD- (log-rank, P = .044; Figure 2A) ; however, we could not confirm any effect of the expression of PD-1 on patient survival (log-rank, P = 1.00; Figure 2B ). Nor did we observe any difference in survival time between PD-1 + and PD-1 − groups among PD-L1 + patients ( Figure S1 ).
Given the fact that presence of FoxO1 phosphorylation by aPKCλ shows strong association with angiosarcoma patient prognosis, 11 the correlation of PD-L1 expression and the presence of pSer218 FoxO1 were analyzed by Fisher's exact test using a 2 × 2 contingency table ( Figure 2C ). The existence of PD-L1 in CAS tissue was strongly correlated with the existence of pSer218 FoxO1
(P = .018). The existence of PD-L1 was also correlated with the existence of aPKCλ, although there was only marginal statistical association (P = .068; Figure 2C ). This is likely due to the limited number of samples in this study. In those patient tissues, immunoreactive signal against pSer218 FoxO1 or aPKC was confirmed in the VEcadherin + and PD-L1 + cells ( Figure 2D ). These results could suggest a functional link between the aPKCλ/pSer218 FoxO1 signaling axis and PD-L1 expression.
| PRKCI gene knockdown suppressed mRNA and protein levels of PD-L1 in HUVECs and AS-M cells
c-Myc, which is regulated by the aPKCλ/pSer218 FoxO1 signaling axis, controls PD-L1 expression. 8 To gain further insight into the relationship between aPKCλ and PD-L1, we used 2 different EC types, Figure 4B ).
| Treatment with ATM suppresses PD-L1 expression
Sodium aurothiomalate is a gold compound that was used for its anti-inflammatory action in the treatment of rheumatoid arthritis. It has recently been rediscovered as an inhibitor of aPKCλ. Activated
Rho family small GTPase Cdc42 binds to partitioning defective protein 6 (PAR-6) to promote the complex formation of PAR-6 with aPKCλ, resulting in aPKCλ activation. 15 Sodium aurothiomalate suppresses the binding of PAR-6 with aPKCλ, thereby inhibiting aPKCλ activation. 16 Additionally, ATM suppresses non-small-cell lung cancer growth in vitro and in animal models. 17 Moreover, clinical investigations targeting aPKCλ in lung cancer are ongoing. 18 We also overexpressed aPKC into HUVECs to examine the effect on PD-L1 expression. Although aPKC KD or pharmacological aPKC inhibition effectively suppressed PD-L1 expression, aPKC overexpression induced only marginal increase in PD-L1 expression ( Figure   S2 ). These observations suggest that aPKC activity is necessary for PD-L1 expression, which would correlate with poor prognosis for angiosarcoma patients (Figure 1 ), but not sufficient to induce PD-L1 expression. Taken together, our results suggest that pharmacological inhibition of aPKCλ reduces not only transformed cell proliferation in CAS but also could improve immune responses of patients for better prognosis through modulating PD-L1 expression.
| D ISCUSS I ON
Programmed cell death ligand 1 is highly expressed in several cancers. In the tumor microenvironment, PD-L1 and its receptor PD-1 play an important role in transformed cell survival by avoiding tumor neutralizing immune surveillance and thereby tumor progression. 3 Tumor cells generally express PD-L1, whereas a variety of immune cells express PD-1. 2 Although immunotherapy using Abs targeting PD-1/PD-L1 is a novel and exciting approach for the field of cancer, the benefit of immunotherapy is limited to specific types of cancers. This might be due to the heterogeneous expression of PD-1 and PD-L1 in the tumor microenvironment 19 or it might be due to post-translational modification. 20 The expression of PD-L1 correlates with the poor prognosis of patients with few exceptions, such as Merkel cell carcinoma. 21 The and granulocyte-macrophage colony-stimulating factor upregulate PD-L1 expression. 22, 26 Granulocyte-macrophage colony-stimulating factor and IL-4 are also strong regulators of PD-L2. 27 In IFNγ signaling, interferon regulatory factor-1 can bind to the PD-L1 promoter pression. 26 The PIK3/Akt pathway signaling is a known activator of aPKCλ, 28 concurrently leading to FoxO1 inactivation by its cytoplasmic localization. 29 Hypoxia-inducible factor-1α is also reported to activate aPKCς, which is another aPKC family member. 30 Recently, Casey et al reported that c-Myc, a proto-oncogene, regulates PD-L1 expression directly in some tumor cells, such as T-cell acute lymphoblastic leukemia, melanoma, and non-small-cell lung carcinoma cell lines. 8 Moreover, Cortez et al reported that miR-34 downregulates PD-L1 expression by binding to the 3′-UTR of PD-L1 mRNA. 12 Our previous work revealed that aPKCλ phosphorylates FoxO1 DNAbinding domain (Ser218), controlling c-Myc expression through miR34c abundance, and thereby regulating cell proliferation ( Figure 6 ).
11
Additionally, we have shown PD-L1 expression is regulated downstream of this pathway ( Figure 6 ). Taken together, these observations suggest the potential that pharmacologic inhibition of aPKCλ could suppress cancer cell proliferation and also modulate immune responses in CAS patients. 
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